Adelene Perkins - Infinity Pharmaceuticals Insider

INFI -- USA Stock  

USD 2.31  0.02  0.86%

  Chairman
Ms. Adelene Q. Perkins serves as Chairman of the Board, Chief Executive Officer of the Company. She was Chairman of the Board, President, Chief Executive Officer of Infinity Pharmaceuticals Inc. She has served as our President and Chief Executive Officer since January 2010, President and Chief Business Officer from October 2008 through December 2009 and as our Executive Vice President and Chief Business Officer between September 2006 and October 2008. Ms. Perkins served as Executive Vice President of IPI from February 2006 until its merger with DPI in September 2006 and Chief Business Officer of IPI from June 2002 until the DPI merger. Prior to joining IPI, Ms. Perkins served as Vice President of Business and Corporationrationrate Development of TransForm Pharmaceuticals, Inc., a private pharmaceutical company, from 2000 to 2002. From 1992 to 1999, Ms. Perkins held various positions at Genetics Institute, most recently serving as Vice President of Emerging Business and General Manager of the DiscoverEase business unit. Ms. Perkins has served as a director of the Biotechnology Industry Organization since 2012, a director of Project Hope, a notforprofit social services company since 2013, a director of the Massachusetts Life Sciences Center, a quasipublic agency of the Commonwealth of Massachusetts, since 2014, a director of the Massachusetts Biotechnology Council, a notforprofit organization, since 2014, and a director of Padlock Therapeutics, a privately held biopharmaceutical company since 2015. From 1985 to 1992, Ms. Perkins held a variety of positions at Bain Company, a strategy consulting firm
Age: 57  Chairman Since 2017  MBA    
617-453-1000  http://www.infi.com
Perkins received a B.S. in Chemical Engineering from Villanova University and an M.B.A. from Harvard Business School.

Adelene Perkins Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (28.6) % which means that it has lost $28.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (59.0) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 6 records

CHAIRMAN Since

Isaac BlechEdge Therapeutics
2013
Patrick SoonShiongNantKwest
2015
John AplinEndocyte
2011
Sol BarerEdge Therapeutics
2013
Steven GorlinNantKwest
2014
Yuen KamChina Cord Blood Corporation
2012

Entity Summary

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 22 people.Infinity Pharmaceuticals (INFI) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 22 people. Infinity Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Infinity Pharmaceuticals Leadership Team

Joseph Pearlberg, Vice President - Clinical Development
Melissa Hackel, Vice President - Finance
William Bertrand, Executive Vice President General Counsel
Vito Palombella, Chief Scientific Officer and Executive VP
Jeffrey Berkowitz, Independent Director
Lawrence Bloch, CFO, Executive Vice President Chief Business Officer
Norman Selby, Lead Outside Independent Director
Jose Baselga, Independent Director
Samuel Agresta, Chief Medical Officer
Michael Venuti, Independent Director
Michael Kauffman, Independent Director
Eric Lander, Independent Director
David Beier, Independent Director
Julian Adams, President of RandD
Anthony Evnin, Independent Director
Gwendolyn Fyfe, Independent Director
Sujay Kango, Executive Vice President Chief Commercial Officer
Ian Smith, Independent Director
Adelene Perkins, Chairman of The Board, CEO and Pres

Stock Performance Indicators

Current Sentiment - INFI

Infinity Pharmaceuticals Investor Sentiment

Most of Macroaxis users are currently bullish on Infinity Pharmaceuticals. What is your judgment towards investing in Infinity Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Cryptocurrency Correlation module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins and exchanges.
Search macroaxis.com